Close Menu

NEW YORK – Canaccord Genuity on Wednesday upgraded its rating for Illumina to Buy, with a new price target of $445, based on improving trends in the sequencing instrument maker's core business.

"With a mega-trend like precision medicine, you can only bet against the market-leading technology enabler for so long," Canaccord Genuity Analyst Max Masucci wrote in a note to investors. "Illumina has addressed many of the concerns that led to our July 2019 downgrade of the stock, and we see a bright future for the company as we exit the COVID-19 pandemic."

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

NPR reports that researchers have developed chimeric embryos as part of work toward growing human organs in animals for organ transplants.

According to the Washington Post, the Biden Administration is set to make changes to federal restrictions on fetal tissue research.

In Science this week: approach to isolated trace DNA from archaic humans from sediments, and more.

Texas Monthly looks into the DNA Zoo being collected by Baylor College of Medicine researchers.